IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BRETSCHNEIDER et al.

Appl. No.: 10/594,251

§ 371(c) Date: September 10, 2007

For: 2,4,6-Phenyl-Substituted Cyclic Ketoenols Confirmation No.: 7404

Art Unit: 1624

Examiner: HABTE, KAHSAY

Atty. Docket: 2400.0800000/JMC/CMB/AKN

Third Supplemental Information Disclosure Statement

Mail Stop Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms PTO/SB/08a equivalent and/or PTO/SB/08b equivalent are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. The numbering on this Third Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Second Supplemental Information Disclosure Statement filed on January 25, 2011 in connection with the above-captioned application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication

dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

Applicants have checked the appropriate boxes below.

- 1. Statement under 37 C.F.R. 1.704(d). Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 2. Filing under 37 C.F.R. § 1.97(b). This Information Disclosure Statement is being filed within three months of the date of filing of a national application other than a continued prosecution application (CPA), OR within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, OR before the mailing date of a first Office Action on the merits OR before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

Atty. Dkt. No. 2400.0800000/JMC/CMB/AKN

□ 3.	Filing under 37 C.F.R. § 1.97(c). This Information Disclosure Statement is being		
	filed more than three months after the U.S. filing date AND after the mailing date		
	of the first Office Action on the merits, but before the mailing date of a Final		
	Rejection, or Notice of Allowance, or an action that otherwise closes prosecution		
	in the application.		
	☐ a.	Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each	
		item of information contained in this Information Disclosure	
		Statement was first cited in any communication from a foreign	
		patent office in a counterpart foreign application not more than	
		three months prior to the filing of this Information Disclosure	
		Statement. 37 C.F.R. § 1.97(e)(1).	
	☐ b.	Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that no item	
		of information in this Information Disclosure Statement was cited	
		in a communication from a foreign patent office in a counterpart	
		foreign application and, to my knowledge after making reasonable	
		inquiry, was known to any individual designated in 37 C.F.R.	
		$\S~1.56(c)$ more than three months prior to the filing of this	
		Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).	
	☐ c.	The required fee is provided through online credit card payment	
		authorization in the amount of \$180.00 in payment of the fee	
		under 37 C.F.R. § 1.17(p).	

- A. Filing under 37 C.F.R. § 1.97(d) This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. The required fee is provided through online credit card payment authorization in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p); in addition:
 - a. Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
 - b. Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- 5. The document(s) was/were cited in a search report by a foreign patent office in a counterpart foreign application. Submission of an English language version of the search report that indicates the degree of relevance found by the foreign office

Atty. Dkt. No. 2400.0800000/JMC/CMB/AKN

	is provided in satisfaction of the requirement for a concise explanation of relevance. 1138 OG 37, 38 and MPEP 609.04(a)(III).
⊠ 6.	A concise explanation of the relevance of the non-English language document(s) appears below in accordance with 37 C.F.R. § 1.98(a)(3).
langua	Document FP16, WO 02/17718 A1, is in a foreign language. An English ge equivalent of document FP16 is cited as document US98.
☑ 7.	Copies of documents FP14-FP16 are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), no copies of U.S. patents and patent application publications cited as document US98 on the attached IDS Forms is submitted.
□ 8.	Copies of the documents were cited by or submitted to the Office in an IDS that complies with 37 C.F.R. § 1.98(a)-(c) in Application
	No, filed, which is relied upon for an earlier filing date under 35 U.S.C. \S 120. Thus, copies of these documents are not attached. 37 C.F.R. \S 1.98(d).
9.	No, filed, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached.

Containment, Inc. 329 F.3d 1358 (Fed. Cir. 2003), Applicants submit herewith

- 6 -

Office Actions from the o	o-pending U.S. Patent Ap	plication No,
filed	, as documents	_ to

The identification of these Office Actions is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

Sterne, Kessler, Goldstein & Fox P.L.L.C.

Asha K. Nadipuram Agent for Applicants Registration No. 65,817

Date: March 31, 2011

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600 1335306_1.DOCX